Zacks Investment Research upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research report report published on Tuesday morning. They currently have $22.00 price objective on the stock.
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
Several other analysts have also commented on the stock. Wedbush began coverage on shares of Ascendis Pharma A/S in a research note on Monday, September 26th. They set an outperform rating and a $34.00 target price for the company. TheStreet upgraded shares of Ascendis Pharma A/S from a sell rating to a hold rating in a research report on Tuesday, September 6th. Finally, Leerink Swann restated a buy rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd.
Ascendis Pharma A/S (NASDAQ:ASND) traded up 0.95% during trading on Tuesday, hitting $20.18. 2,462 shares of the company traded hands. Ascendis Pharma A/S has a one year low of $11.92 and a one year high of $21.70. The firm’s market cap is $508.39 million. The firm has a 50 day moving average of $19.30 and a 200 day moving average of $16.14.
Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.10. Ascendis Pharma A/S had a negative net margin of 818.32% and a negative return on equity of 47.61%. On average, analysts expect that Ascendis Pharma A/S will post ($3.14) earnings per share for the current fiscal year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.